News
AstraZeneca’s stock market exit would be devastating blow, warns ex-chancellor - The UK is ‘a hostile environment’ for ...
Shares of AstraZeneca PLC AZN shed 1.66% to £104.50 Friday, on what proved to be an all-around dismal trading session for the ...
AstraZeneca PLC closed 20.63% short of its 52-week high of £133.88, which the company achieved on September 3rd.
AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...
AstraZeneca PLC (NASDAQ:AZN) is one of the 10 best defensive stocks to buy in a volatile market. On July 4, the company ...
9don MSN
AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...
AstraZeneca Plc’s shares rose after a report that Chief Executive Officer Pascal Soriot wants to move the British drugmaker’s ...
AstraZeneca may have washed its hands of AZD4041 after the opioid use disorder (OUD) prospect demonstrated a potential drug-drug interaction last year, but the pharma’s development partner, Eolas T | ...
Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.
The deal gives AstraZeneca’s rare disease unit Alexion access to specialized capsids developed by the Japanese biotech JCR ...
"attachment_1220866" align="aligncenter" width="1456"] A laboratory employee in a sterile environment inspecting a microscope ...
London marked the slowest first half-year for IPO volume since 1997, a grim milestone punctuated by a report that AstraZeneca ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results